Natamycin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: Ophthalmic Fungal keratitis As 5% ophthalmic susp: Instill 1 drop into the conjunctival sac of the affected eye(s) 1-2 hourly, reduce to 1 drop 6-8 times daily after 3-4 days. Duration of treatment: 2-3 weeks. Gradually reduce dose at 4-7 day intervals. Fungal blepharitis; Fungal conjunctivitis As 5% ophthalmic susp: Instill 1 drop into the conjunctival sac of the affected eye(s) 4-6 times daily.
Contraindications
Hypersensitivity.
Special Precautions
Patient with epithelial ulceration. Pregnancy and lactation. Patient Counselling Avoid use of contact lenses during treatment. Monitoring Parameters Assess for treatment effectiveness; if no improvement after 7-10 days, re-evaluate therapy.
Adverse Reactions
Cardiac disorders: Chest pain. Eye disorders: Changes in vision, corneal opacity; eye discomfort, oedema, hyperaemia, irritation, pain, foreign body sensation, paraesthesia, tearing. Immune system disorders: Allergic reaction. Respiratory, thoracic and mediastinal disorders: Dyspnoea.
ATC Classification
D01AA02 - natamycin ; Belongs to the class of antibiotics. Used in the topical treatment of fungal infection.
S01AA10 - natamycin ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
A01AB10 - natamycin ; Belongs to the class of local antiinfective and antiseptic preparations. Used in the treatment of diseases of the mouth.
A07AA03 - natamycin ; Belongs to the class of antibiotics. Used in the treatment of intestinal infections.
G01AA02 - natamycin ; Belongs to the class of antibiotics. Used in the treatment of gynecological infections.
Disclaimer: This information is independently developed by CIMS based on natamycin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in